43 news items
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
in personalized medicine and, through innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
BMY
1 Jun 24
, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY
30 May 24
changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
BMY
23 May 24
, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data
jg0uk ukiin384vzsolp6yfda6p4y5f725lbog0pe
BMY
22 May 24
Squibb, an innovator in the immuno-oncology space, join our oversubscribed Series B extension round. The funding strengthens NeoPhore's position
hykqutxp7avbsmd2q
BMY
21 May 24
is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases
6ylzcnw3d1khpf25h1ug7afl3062mitgs
BMY
16 May 24
development, Immunology, Cardiovascular and Neuroscience, Bristol Myers Squibb. "Our leadership in TYK2 innovation highlights our transformational science
2hw1b o9sidvqgd5d5h0g0yhj2vhf16j8jegnr6f85t39amai
BMY
15 May 24
innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding of causal human biology, cutting-edge
im8od3ovht7lasn3trt7b5ea 3h284
BMY
10 May 24
Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights
h95zq94au51c2dgw6unfaqpod565cob9pc14lpmllt7fcqb534
BMY
29 Apr 24
-leading expertise in developing and commercializing innovative immune medicines
825pebdc ruvjek431l9epgwi51yv2dd0ra95oa6qry4jygj3p6txv
BMY
26 Apr 24
expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms
dnlipns dcapq0d8d5v4a863d90gp9h3oeyqv
BMY
25 Apr 24
Initiative to Deliver ~$1.5 Billion in Cost Savings, the Majority of Which Will be Reinvested to Fund Innovation and Drive Growth
iy9409c8lria1dt0wr0aa5y 3fb8ldtdt59j9y2hechfszu2
ABBV
ATNM
AZN
19 Apr 24
, the biotech industry stands out as a beacon of innovation and growth potential. Actinium Pharmaceuticals, Inc
l4pnxjmtplai5e3owkpjrjsnk78g5
ATNM
AZN
BMY
18 Apr 24
biotech sector continues to benefit from favorable financing conditions and a vibrant outlook for mergers and acquisitions, coupled with innovative